1082 studies found for:    Ovarian Cancer: Clinical Trials
Show Display Options
Rank Status Study
21 Recruiting Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) in Ovarian Cancer Recurrence
Condition: First Recurrence of Ovarian Cancer
Interventions: Procedure: Secondary citoreduction;   Procedure: Hyperthermic intra-peritoneal chemotherapy (HIPEC)
22 Recruiting Autologous OC-DC Vaccine in Ovarian Cancer
Conditions: Chemotherapy;   Tumor;   Ovarian Cancer
Intervention: Biological: OCDC
23 Completed
Has Results
Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Primary Peritoneal Cancer
Interventions: Drug: Pemetrexed - Phase 1;   Drug: Carboplatin - Phase 1;   Drug: Pemetrexed - Phase 2;   Drug: Carboplatin - Phase 2
24 Terminated
Has Results
Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients
Condition: Ovarian Cancer
Interventions: Biological: Abagovomab;   Biological: Placebo
25 Recruiting Phase 1/2 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR)
Condition: Ovarian Cancer
Intervention: Drug: IMAB027
26 Completed
Has Results
A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer
Conditions: Epithelial Ovarian Cancer;   Extraovarian Peritoneal Cancer;   Fallopian Tube Carcinoma
Intervention: Drug: Ontak
27 Completed A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Peritoneal Cancer
Intervention: Biological: DCVac-L
28 Terminated
Has Results
A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian Cancer
Conditions: Epithelial Ovarian Cancer;   Extraovarian Peritoneal Cancer;   Fallopian Tube Carcinoma
Intervention: Drug: Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2a
29 Recruiting Intraperitoneal Aerosol High-pressure Chemotherapy for Women With Recurrent Ovarian Cancer
Condition: Recurrent Ovarian Cancer
Intervention: Drug: chemotherapy with doxorubicin and cisplatin
30 Active, not recruiting Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer
Intervention: Procedure: Tumor collection
31 Completed
Has Results
Open Trial of Bendamustine Hydrochloride in Women With Advanced Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Drug: Bendamustine HCL
32 Recruiting A Clinical Trial in Patients With BRCA Defective Tumours
Conditions: Breast Cancer;   Ovarian Cancer
Interventions: Drug: 6-Mercaptopurine;   Drug: Methotrexate
33 Recruiting Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: Pimasertib once daily;   Drug: Pimasertib placebo;   Drug: SAR245409 placebo;   Drug: SAR245409;   Drug: Pimasertib twice daily
34 Suspended Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: Doxil (Pegylated Liposomal Doxorubicin);   Drug: BIBF 1120
35 Recruiting Trial of Vaccine Therapy in Recurrent Platinum Sensitive Ovarian Cancer Patients
Condition: Recurrent Epithelial Ovarian Cancer
Intervention: Biological: DC-006 vaccine
36 Recruiting Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial
Conditions: Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Carcinoma
Interventions: Drug: Paclitaxel(intravenous) + Carboplatin(intravenous);   Drug: Paclitaxel(intravenous) + Carboplatin(intraperitoneal)
37 Active, not recruiting Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study
Condition: Epithelial Ovarian Cancer
Intervention: Biological: MUC1 Dendritic Cell Vaccine (Cvac)
38 Completed Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Intervention: Drug: imatinib mesylate
39 Recruiting Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy in Patients With Recurrent Ovarian Cancer
Condition: Recurrent Epithelial Ovarian Cancer
Intervention: Drug: Catumaxomab
40 Active, not recruiting BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer
Condition: Ovarian Neoplasms
Interventions: Drug: Paclitaxel;   Drug: Gemcitabine;   Drug: Topotecan;   Drug: Pegylated liposomal doxorubicin (PLD);   Drug: BI 6727

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years